<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00991861</url>
  </required_header>
  <id_info>
    <org_study_id>H 569 000 - 0908</org_study_id>
    <secondary_id>EudraCT: 2009-012063-33</secondary_id>
    <nct_id>NCT00991861</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis</brief_title>
  <official_title>Double-blind, Randomized, Multi-centre Phase II Study to Evaluate the Efficacy and Safety of Topically Applied LAS41007 Once Daily and LAS41007 Twice Daily Versus LAS106521 Gel Twice Daily in the Treatment of Actinic Keratosis Grade I to II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Almirall, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Almirall, S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the efficacy, safety and tolerability of either a once
      or twice daily topical application of LAS41007 compared to a twice daily application of
      LAS106521 in the treatment of actinic keratosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histological clearance of one pre-selected target lesion</measure>
    <time_frame>Day 120</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete clinical clearance of all target lesions in the treatment areas</measure>
    <time_frame>Day 120</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Tolerability Assessment (PGT)</measure>
    <time_frame>Day 120</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>LAS41007 o.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAS41007 b.i.d.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAS106521</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS41007 o.d.</intervention_name>
    <description>Once daily, topical application</description>
    <arm_group_label>LAS41007 o.d.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS41007 b.i.d.</intervention_name>
    <description>Twice daily, topical application</description>
    <arm_group_label>LAS41007 b.i.d.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAS106521</intervention_name>
    <description>Twice daily, topical application</description>
    <arm_group_label>LAS106521</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 4-10 clinically assessed actinic keratosis grade I to II (according to Olsen
             et al, 1991) in the face/forehead and/or on the bald scalp

          -  The diameter of each AK target lesion is not less than 0.5 cm and not greater than 1.5
             cm

          -  The target lesions must be located in overall 2 treatment areas with a size of 25 cm2
             per treatment area

        Exclusion Criteria:

          -  Have evidence of clinically significant or unstable medical conditions such as:

               -  metastatic tumor or tumor with high probability of metastatic spread

               -  heart failure (NYHA class III or higher)

               -  immunosuppressive disorder (e.g. HIV)

               -  hematologic, hepatic, renal, neurologic or endocrine disorder.

               -  collagen-vascular disorder (e.g. cerebrovascular disorder or other bleedings).

               -  gastrointestinal disorder (e.g. active ulcera or history of recurrent peptic
                  ulcera or hemorrhage)

          -  Suffer from paresthesia in the treatment areas

          -  Show Cornu cutaneum of the skin and/or hypertrophic AK lesions in the treatment areas
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Willers, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Almirall Hermal GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.almirall.com/webcorp2/cda/ImD_04_02.jsp</url>
    <description>Almirall Corporate Website</description>
  </link>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2009</study_first_submitted>
  <study_first_submitted_qc>October 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2009</study_first_posted>
  <last_update_submitted>May 28, 2015</last_update_submitted>
  <last_update_submitted_qc>May 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic Keratosis</keyword>
  <keyword>AK</keyword>
  <keyword>NMSC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

